^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Yutuo (zimberelimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 3275: GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial
Published date:
05/15/2020
Excerpt:
For pan-caner analysis, ORR benefits of GLS-010 were also enhanced (51.9% versus 26.4%, p=0.0298) in pts with tTMB-high (>75th percentile, of each tumor type) versus tTMB-low. Pairing tTMB and survival data were analyzed in 129 pts, and tTMB-high pts benefit more with a significantly improved PFS (p=0.011). Also, improved PFS was observed in tTMB-high pts with EC (p=0.0059). For bTMB-high group, pts with EC achieved higher ORR (42.9% vs 6.3%, p=0.0672), which translated into PFS benefits (p=0.03).
DOI:
10.1158/1538-7445.AM2020-3275
